Tag: C.R. Bard
Liberator ends year with uptick in sales
December 15, 2015HME News Staff
STUART, Fla. - Liberator Medical, which is being acquired by manufacturer C.R. Bard, posted a 9.4% increase in net sales for the fiscal year ended Sept. 30, 2015.Net sales were $81.6 million in 2015 vs. $74.6 million in 2014, driven primarily by the company's continued emphasis on direct response advertising.“In 2015, we expanded the scope and reach of our sales and marketing activities, and strengthened our customer base through our proven direct response advertising efforts,” stated...
Liberator strengthens C.R. Bard's direct-to-consumer platform
November 25, 2015Theresa Flaherty, Managing Editor
STUART, Fla. - Liberator Medical got a “strong price” when it sold to C.R. Bard recently, analysts say.
Bard, a manufacturer of medical devices for vascular, urology, oncology and surgical specialty fields, agreed to pay $181 million for the provider of home medical supplies, including catheters, ostomy, diabetes and mastectomy.
“That's a very strong price for sure,” said Rick Glass, president of Steven Richards & Associates. “Without a distributor or middleman...
Device maker buys Liberator Medical
November 20, 2015HME News Staff
MURRAY HILL, N.J. - C.R. Bard, a manufacturer of medical devices for vascular, urology, oncology and surgical specialty fields, announced today that it has acquired Liberator Medical for $181 million.Liberator is a director-consumer-provider of home medical supplies, including catheters, ostomy, diabetes and mastectomy.“As the population ages and more healthcare is expected to occur outside of the hospital setting, we believe that having direct access to the patient in the home is strategically...
In brief: Prodigy responds to FDA, Sunrise launches program
September 6, 2013HME News Staff
CHARLOTTE, N.C. - Prodigy Diabetes Care has conducted a regulatory assessment by an independent auditor to examine, review and revise certain procedures and training to ensure compliance with FDA requirements, it told patients, caregivers and partners in a Sept. 4 letter.
“Prodigy assures you that this attention to improvement is an ongoing effort to ensure full compliance,” stated CEO Richard Admani in the letter.
In a Feb. 22 letter, the FDA warned Prodigy about numerous violations,...
Bard to acquire Rochester Medical
September 5, 2013HME News Staff
MURRAY HILL, N.J. - C.R. Bard and Rochester Medical, two players in the urology market, announced Sept. 4 that they have entered into an agreement to merge. The deal is expected to close later this year, with Bard paying $20 per share, about $262 million, for Rochester. “Rochester's double-digit growth product portfolio, including their customer access programs, is a key building block in our strategy to access faster growing markets over the long-term,” stated Timothy Ring, Bard...